At 22.4% CAGR, the South & Central America Organoids Market is Projected to be Worth US$ 806.23 Million by 2031, Says Business Market Insights

According to Business Market Insights research, the South & Central America organoids market was valued at US$ 160.44 million in 2023 and is expected to reach US$ 806.23 million by 2031, registering a CAGR of 22.4% from 2023 to 2031. Focus on drug discovery activities and combination of organoids and organ-on-a-chip are among the critical factors attributed to the South & Central America organoids market expansion.

The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. According to ClinicalTrials.gov, the total number of clinical trial studies in 2021 was estimated at 384,288. A recent survey by the HUB states that organoids can potentially make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug and omitting them from clinical trials. An increasing number of clinical trials worldwide is expected to drive the demand for advanced medical technologies, including organoid models. Organoids in drug discovery are not limited to just cancer; they are also used in other disease studies, including cystic fibrosis, polycystic kidney disease, microcephaly, and gut and airway infections. For instance, organoids can summarize the properties of an organ, such as organ structure and function. They can also restore the original genetic and epigenetic state of a tissue or an organ, making them suitable for gene editing.

Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has led to breakthroughs in cystic fibrosis treatment. According to the study "CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank," published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not optimal. Therefore, R&D regarding safety, long-term stability, and functionality of gene-edited organoids becomes crucial. Thus, the continued focus on drug discovery activities to tap the untapped areas of medicine offers more significant growth opportunities for the organoids market.

On the contrary, dearth of skilled professionals hampers the growth of South & Central America organoids market.

Based on type, the South & Central America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held 23.0% share of the South & Central America organoids market in 2023, amassing US$ 36.86 million. It is projected to garner US$ 181.83 million by 2031 to expand at 22.1% CAGR during 2023–2031.

Based on application, the South & Central America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.9% share of the South & Central America organoids market in 2023, amassing US$ 47.99 million. It is projected to garner US$ 252.32 million by 2031 to expand at 23.1% CAGR during 2023–2031.

Based on source, the South & Central America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 72.2% share of the South & Central America organoids market in 2023, amassing US$ 115.76 million. It is projected to garner US$ 600.18 million by 2031 to expand at 22.8% CAGR during 2023–2031.

Based on offering, the South & Central America organoids market is segmented into instruments, consumables, and services. The consumables segment held 59.6% share of the South & Central America organoids market in 2023, amassing US$ 95.59 million. It is projected to garner US$ 479.07 million by 2031 to expand at 22.3% CAGR during 2023–2031. The instruments segment is further subsegmented into devices and equipment. The consumables segment is further subsegmented into sensors and others.

Based on method, the South & Central America organoids market is segmented into micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion, and others. The hanging drop segment held 48.1% share of the South & Central America organoids market in 2023, amassing US$ 77.12 million. It is projected to garner US$ 384.14 million by 2031 to expand at 22.2% CAGR during 2023–2031.

Based on country, the South & Central America organoids market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil held 44.7% share of South & Central America organoids market in 2023, amassing US$ 71.76 million. It is projected to garner US$ 369.01 million by 2031 to expand at 22.7% CAGR during 2023–2031.

Key players operating in the organoids market are STEMCELL Technologies Inc; Molecular Devices, LLC.; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA; InSphero; ACRO Biosystems; Bio-Techne Corp; SUN bioscience SA; ORGANOID SCIENCES Co., Ltd.; Crown Bioscience Inc; Sartorius AG; 3D Biotek LLC; Prellis Biologics Inc.; 3Dnamics Inc.; and Cellesce Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com